Combined Treatment of Tanshinone I and Epirubicin Revealed Enhanced Inhibition of Hepatocellular Carcinoma by Targeting PI3K/AKT/HIF-1α.
Jiali ZhaoEn LinChaonong CaiManyao ZhangDecheng LiShanglin CaiGuifang ZengZeren YinBo WangPeiping LiXiaopeng HongJiafan ChenBaojia ZouJian LiPublished in: Drug design, development and therapy (2022)
Our results suggested that Tan I could effectively improve the anti-tumor effect of EADM, and synergize EADM to reverse HIF-1α mediated resistance via targeting PI3K/AKT/HIF-1α signaling pathway.